Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) is sponsored by National Institute of Allergy and Infectious Diseases (NIAID). The ReVAMPP network researches pathogens that currently lack effective treatments and vaccines, with a focus on developing new antibodies and vaccines for diseases with pandemic potential.

Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) | NIAID: National Institute of Allergy and Infectious Diseases Resources for Researchers Division of Intramural Research Labs Research at Vaccine Research Center Intramural Scientist & Clinician Directory Research Rules & Policies Allergy, Immunology & Transplantation Resources for Researchers Antimicrobial (Drug) Resistance Antimicrobial Resistance Threats Information for Researchers Risk Factors & Prevention Research Immune Tolerance Processes Disease-Specific Research Information for Researchers Autoimmune Lymphoproliferative Syndrome (ALPS) Basic & Preclinical Research Information for Researchers Information for Researchers Shiga Toxin-Producing E.

coli (STEC) Researching Ebola in Africa Information for Researchers Information for Researchers Why Food Allergy is a Priority for NIAID Characterizing Food Allergy & Addressing Related Disorders Information for Researchers Diagnosis & Management Guidelines Disease-Specific Research Information for Researchers Genomics & Advanced Technologies Pathogen-Based Initiatives Information for Researchers Information for Researchers Group A Streptococcal Infections Disease-Specific Research Information for Researchers Overview of the Immune System Features of an Immune Response Information for Researchers Information for Researchers Leprosy (Hansen's Disease) How NIAID is Addressing Lyme Disease Information for Researchers Parasite, Mosquito & Human Host Prevention, Treatment & Control Strategies Strategic Partnerships & Research Capacity Information for Researchers Information for Researchers Neglected Tropical Diseases Information for Researchers Translational & Clinical Research Cross-cutting Preparedness Molecular & Genetic Research Primary Immune Deficiency Diseases (PIDDs) Information for Researchers Animal Prion Diseases and Humans Information for Researchers Respiratory Syncytial Virus (RSV) Schistosomiasis (Bilharzia) Research in Endemic Regions Sexually Transmitted Infections (STIs) NIAID's Research Approach Information for Researchers Disease-Specific Research Information for Researchers Information for Researchers Disease-Specific Vaccines Information for Researchers Translational & Clinical Research Information for Researchers Biology, Genetics & Clinical Research NIAID's Approach to Women's Health Research Sex-Specific Health Challenges Facing Women Biennial Report (FY 2019-2020) Information for Researchers Why NIAID Is Researching Zika Virus Information for Researchers Find a Funding Opportunity Opportunities & Announcements NIAID Research Priorities Plan Your Budget & Personnel Additional Application Elements Research with Special Considerations After You Submit an Application Funding Policies and Considerations Understand the Review Process Respond to Pre-Award Requests Negotiation & Initial Award Become a Healthy Volunteer Participant's Guide to Clinical Trials HIV and Emerging Infectious Diseases Laboratory of Infectious Diseases Primary Immune Deficiency Clinic Vaccine Research Center Clinical Studies Fill Out the Volunteer Form Q&A: Vaccine Clinical Studies Vaccine Clinical Studies Safeguards Clinical Trial Publications NIAID-Funded Research News Division of Allergy, Immunology, and Transplantation Division of Microbiology and Infectious Diseases Division of Extramural Activities Division of Clinical Research Division of Intramural Research Dr. Joseph J.

Kinyoun: Father of the NIH Dr. Joseph Kinyoun The Indispensable Forgotten Man Dr. Joseph Kinyoun: Selected Bibliography NIAID 60th Anniversary Timeline Research Training at NIAID Campuses Grant Programs that NIAID Funds AIDS Research Advisory Committee AIDS Vaccine Research Subcommittee Board of Scientific Counselors Members Advisory and Peer Review Committees Autoimmune Diseases Committee Website Policies and Notices External Link Icon and Disclaimers Freedom of Information Act (FOIA) Voluntarily Submitted Information Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) In the wake of COVID-19, the need for rapid response research has become increasingly apparent.

The Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network conducts basic and translational research on representative viruses within a specific virus family, with the goal of developing effective vaccines and monoclonal antibodies for other viruses within that family.

By leveraging the “prototype pathogen” approach, the ReVAMPP network lay the groundwork for a faster and more effective pandemic response, should a virus from one of the targeted families emerge as a pandemic threat. Currently, there are no vaccines or targeted therapeutics for many diseases caused by the selected virus families. The awards have been made to seven different US based research groups and one coordinating center.

The Network works with NIAID, USG and global partners to share information and collaborate. ReVAMPP is a rapid response research network designed to conduct fundamental basic through IND-enabling translational research on representative viruses, or “prototype pathogens,” within specific virus families.

The virus families that the ReVAMPP network study contain many viruses that have caused human disease for millennia—many of which have a high likelihood of becoming pandemic threats in the future.

The ReVAMPP network focuses on viruses from the Flaviviridae family, which features viruses that cause dengue and yellow fever; the Paramyxoviridae family, which contains viruses that cause measles, mumps, and Nipah-induced encephalitis; the Picornaviridae family, whose members cause poliomyelitis, foot-and-mouth disease, and myocarditis; the Togaviridae family, which contains viruses that induce Chikungunya virus-induced arthralgia or encephalitis and Venezuelan equine encephalitis; as well as viruses from 5 different families within the Bunyavirales order, including Sin Nombre virus from the Hantaviridae family and the viruses that cause Rift Valley Fever (Phenuiviridae), Crimean Congo Hemorrhagic Fever (Nairoviridae), Oropouche Fever (Peribunyaviridae), and Lassa Fever (Arenaviridae).

The 9 viral families covered by the ReVAMPP network are: RTI International will lead a centralized Coordination and Data Sharing Center, to provide support and coordination for the network. By standardizing methodologies, such as reagents, animal models, and data outputs, research centers that comprise the ReVAMPP network are able to easily share their results and collaborate to enhance the network’s efforts.

The award recipients are: Albert Einstein College of Medicine, Bronx, NY Project title: PROVIDENT: Prepositioning Optimized Strategies for Vaccines and Immunotherapeutics against Diverse Emerging Infectious Threats Principal investigator: Kartik Chandran, Ph. D.

Research Triangle Institute (RTI) International, Research Triangle Park, NC Project title: Coordinating and Data Sharing Center - R&D of Vaccines and Antibodies for Pandemic Preparedness (ReVAMPP) Principal investigator: Gregory D. Sempowski, Ph. D.

University of California, Irvine, CA Project title: The UCI Vaccines for Pandemic Preparedness Center (VPPC) Principal investigator: Louis Philip Felgner, Ph. D. University of Texas Medical Branch, Galveston, TX Project title: Paramyxoviridae and Bunyavirales Vaccines and Antibodies Center (PABVAX) Principal investigator: Thomas William Geisbert, Ph.

D. University of Washington, Seattle, WA Project title: Machine learning-enabled design of prototype pathogen vaccines and antibodies Principal investigator: Neil King, Ph. D.

Vanderbilt University Medical Center, Nashville, TN Project title: Bunyavirus and Picornavirus Pandemic Pathogen Preparedness (BP4) Center Principal investigator: James E. Crowe, Jr., M. D.

Washington University, St. Louis, MO Project title: Flavivirus and Alphavirus ReVAMPP (FLARE) Principal investigator: Michael S. Diamond, M.

D. , Ph. D.

Washington University, St. Louis, MO Project title: Vaccines and Therapeutic Antibodies to Respiro, Rubula, Peribunya and Phenuiviridae (R2P2)-ReVAMPP Principal investigator: Sean P. J.

Whelan, Ph. D. View the ReVAMPP clinical/hospital/study and laboratory locations in a larger map NIAID Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Contact Content last reviewed on November 18, 2024